

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM491836

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
AMICUS THERAPEUTICS, INC.		09/28/2018	Corporation: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	BIOPHARMA CREDIT PLC		
<b>Street Address:</b>	c/o Beaufort House, 51 New North Road		
<b>City:</b>	Exeter		
<b>State/Country:</b>	UNITED KINGDOM		
<b>Postal Code:</b>	EX4 4EP		
<b>Entity Type:</b>	Public Limited Company: UNITED KINGDOM		
<b>PROPERTY NUMBERS Total: 5</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	5541266	GALAFOLD	
<b>Serial Number:</b>	86839457	GALAFOLD	
<b>Serial Number:</b>	86839465		
<b>Serial Number:</b>	86839473	GALAFOLD	
<b>Serial Number:</b>	86839478		
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	2128721002		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	2128728078		
<b>Email:</b>	alui@akingump.com, kkoehler@akingump.com		
<b>Correspondent Name:</b>	Amanda Lui		
<b>Address Line 1:</b>	One Bryant Park		
<b>Address Line 4:</b>	New York, NEW YORK 10036		
<b>NAME OF SUBMITTER:</b>	Kwan Koehler		
<b>SIGNATURE:</b>	/Kwan Koehler/		
<b>DATE SIGNED:</b>	09/28/2018		
<b>Total Attachments: 6</b>			
source=Pharmakon-Fold -- Trademark Security Agreement (Executed)#page1.tif			

CH \$140.00 5541266

source=Pharmakon-Fold -- Trademark Security Agreement (Executed)#page2.tif  
source=Pharmakon-Fold -- Trademark Security Agreement (Executed)#page3.tif  
source=Pharmakon-Fold -- Trademark Security Agreement (Executed)#page4.tif  
source=Pharmakon-Fold -- Trademark Security Agreement (Executed)#page5.tif  
source=Pharmakon-Fold -- Trademark Security Agreement (Executed)#page6.tif

## TRADEMARK SECURITY AGREEMENT

THIS TRADEMARK SECURITY AGREEMENT, dated as of September 28, 2018, is made by AMICUS THERAPEUTICS, INC. (“Grantor”), in favor of BIOPHARMA CREDIT PLC (together with its successors and permitted assigns, “Lender”) on behalf of itself and the other Secured Parties (as defined in the Loan Agreement referred to below).

### WITNESSETH:

WHEREAS, pursuant to the Loan Agreement, dated as of September 19, 2018 (as the same may be amended, restated, supplemented or otherwise modified from time to time, the “Loan Agreement”), by and among AMICUS THERAPEUTICS, INC. (“Borrower”), CALLIDUS BIOPHARMA, INC. (as an additional Credit Party), SCIODERM, INC. (as an additional Credit Party), MIAMED, INC. (as an additional Credit Party), AMICUS THERAPEUTICS US, INC. (as an additional Credit Party), AMICUS BIOLOGICS, INC. (as an additional Credit Party), CELENEX, INC. (as an additional Credit Party) and Lender, Lender has agreed to make extensions of credit to Borrower upon the terms and subject to the conditions set forth therein;

WHEREAS, Grantor has agreed, pursuant to a Guaranty and Security Agreement dated as of September 28, 2018 in favor of Lender for the benefit of itself and the other Secured Parties (as such agreement may be amended, restated, supplemented or otherwise modified from time to time, the “Guaranty and Security Agreement”), to guarantee the Obligations (as defined in the Loan Agreement) of Borrower; and

WHEREAS, Grantor is party to the Guaranty and Security Agreement pursuant to which Grantor is required to execute and deliver this Trademark Security Agreement;

NOW, THEREFORE, in consideration of the mutual covenants, terms and conditions set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree, intending to be legally bound, as follows:

Section 1. Defined Terms. Capitalized terms used herein without definition are used as defined in the Guaranty and Security Agreement.

Section 2. Grant of Security Interest in Trademark Collateral. Grantor, as collateral security for the prompt and complete payment and performance when due (whether at stated maturity, by acceleration or otherwise) of the Secured Obligations, hereby mortgages, pledges and hypothecates to Lender, for the benefit of itself and the other Secured Parties, and grants to Lender, for the benefit of itself and the other Secured Parties, a Lien on and security interest in, all of its right, title and interest in, to and under the following Collateral of Grantor, in each case, solely to the extent constituting Collateral (and excluding any Excluded Property) (the “Trademark Collateral”):

1.1.1. all of its Trademarks and all IP Licenses and IP Ancillary Rights providing for the grant by or to Grantor of any right under any Trademark,

including, without limitation, those referred to on Schedule 1 hereto, but excluding any “intent to use” Trademark applications for which a statement of use has not been filed (but only excluding such applications until such statement is filed);

1.1.2. all renewals and extensions of the foregoing;

1.1.3. all goodwill of the business connected with the use of, and symbolized by, each such Trademark; and

1.1.4. all income, royalties, proceeds and liabilities at any time due or payable or asserted under and with respect to any of the foregoing, including, without limitation, all rights to sue and recover at law or in equity for any past, present and future infringement, misappropriation, dilution, violation or other impairment thereof.

Section 3. Guaranty and Security Agreement. The security interest granted pursuant to this Trademark Security Agreement is granted in conjunction with the security interest granted to Lender for the benefit of itself and the other Secured Parties, pursuant to the Guaranty and Security Agreement and Grantor hereby acknowledges and agrees that the obligations, rights and remedies of Grantor and of Lender on behalf of itself and the other Secured Parties with respect to the security interest in the Trademark] Collateral made and granted hereby are more fully set forth in the Guaranty and Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein.

Section 4. Grantor Remains Liable. Grantor hereby agrees that, anything herein to the contrary notwithstanding, Grantor shall assume full and complete responsibility for the prosecution, defense, enforcement or any other reasonably necessary actions in connection with their [Copyrights] [Patents] [Trademarks] and IP Licenses subject to a security interest hereunder.

Section 5. Counterparts. This [Copyright] [Patent] [Trademark] Security Agreement may be executed in any number of counterparts and by different parties in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Signature pages may be detached from multiple separate counterparts and attached to a single counterpart.

Section 6. Governing Law. This [Copyright] [Patent] [Trademark] Security Agreement and the rights and obligations of the parties hereto shall be governed by, and construed and interpreted in accordance with, the law of the State of New York without regard to any principle of conflicts of law that could require the application of the law of any other jurisdiction.

[Signature Page Follows]

IN WITNESS WHEREOF, Grantor has caused this Trademark Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

Very truly yours,

Amicus Therapeutics, Inc.,  
as Grantor

By: 

Name: Bradley L. Campbell

Title: President

*Signature Page to the Trademark Security Agreement*

**TRADEMARK**  
**REEL: 006472 FRAME: 0891**

ACCEPTED AND AGREED  
as of the date first above written:

BIOPHARMA CREDIT PLC,  
as Lender

By: Pharmakon Advisors, LP,  
its Investment Manager

By: Pharmakon Management I, LLC,  
its General Partner

By:   
Name: Pedro Gonzalez de Cosio  
Title: Managing Member





*Signature Page to the Trademark Security Agreement*

**TRADEMARK**  
**REEL: 006472 FRAME: 0892**

SCHEDULE I  
TO  
TRADEMARK SECURITY AGREEMENT

Trademarks, Trademark Applications  
(including any service marks, collective marks and certification marks) and Trademark Licenses

All Trademarks listed below are owned by Amicus Therapeutics, Inc.

Amicus No.	LSI No.	Country	Image Title	Trademark	Status	Application No.	Application Date	Registration No.	Registration Date	Class/Goods
<b>North America</b>										
GAL-4BE-US	3114732	United States		GALAFOLD	Registered	86465401	11/26/2014	5,541,266	8/14/2018	Class 5: Pharmaceutical preparations for the treatment of Fabry disease
GAL-3BE-US	3114743	United States		GALAFOLD & Design (No Color Claim - Black & White)	Allowed	86839457	12/4/2015			Class 5: Pharmaceutical preparations for the treatment of Fabry disease.
GAL-2BE-US	3114744	United States		Galafold Design Logo (No Color Claim - Black & White)	Allowed	86839465	12/4/2015			Class 5: Pharmaceutical preparations for the treatment of Fabry disease.
GAL-3CE-US	3114745	United States		GALAFOLD & Design (Color Claim)	Allowed	86839473	12/4/2015			Class 5: Pharmaceutical preparations for the treatment of Fabry disease.
GAL-2CE-US	3114746	United States		Galafold Design Logo (Color Claim)	Allowed	86839478	12/4/2015			Class 5: Pharmaceutical preparations for the treatment of Fabry disease.